Zenas BioPharma, Inc.
NASDAQ:ZBIOBiotechnology
+$0.64 today
- Market cap
- $1.79B
- Beta
- -0.69
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$7.64
Volume 0.48M
Average 0.71M
ZBIO Total Liabilities
Everything the company owes to creditors and other parties.
Zenas BioPharma, Inc.NASDAQ: ZBIO
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities rises 732.9% from a year ago
Total liabilities stood at $411.85M at the end of Q1 FY2026, up 732.9% from a year earlier and up 191.1% from the prior quarter. Over 3 fiscal years it compounded at -19.1% a year.
Context
- Total liabilities amounted to 55.1% of total assets at the end of Q1 FY2026, up 40.3 pp from a year earlier.
- Total liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +732.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 141.5M USD
- Year-over-year change
- +146.0%
- 3-year CAGR
- -19.1%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 141.5M | +146.0% |
| FY2024 | 2024-12-31 | 57.51M | -80.4% |
| FY2023 | 2023-12-31 | 293.9M | +10.1% |
| FY2022 | 2022-12-31 | 266.87M | — |
Total Liabilities vs competitors
How ZBIO compares with its peers on the latest reported figures
- ZBIO's Mar 2026 total liabilities of $411.85M is the highest of the 8 companies compared; the peer median is $33.11M.
- Its year-over-year change of +732.9% is the highest of 8, against a peer median of +33.1%.
- Total liabilities amounts to 55.1% of total assets for ZBIO, versus a peer median of 22.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $411.85M | +732.9% | -19.1% | 55.1% | |
| Sep 2026 | $104.02M | +64.5% | +34.3% | 13.7% | |
| Mar 2026 | $58.36M | -1.5% | +6.9% | 22.2% | |
| Mar 2026 | $55.07M | +1.9% | +0.2% | 27.7% | |
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | $33.11M | +108.5% | — | 11.4% |
| Mar 2026 | $17.36M | -79.1% | -53.2% | 27.3% | |
UPBUpstream Bio, Inc. | Mar 2026 | $14.06M | +33.1% | -51.7% | 4.4% |
| Dec 2025 | $11.44M | +55.7% | +18.3% | 99.5% | |
| Peer median (excluding ZBIO) | $33.11M | +33.1% | +3.6% | 22.2% | |
Competitors are the stored peer set for ZBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Zenas BioPharma, Inc.
NASDAQ:ZBIO
Intrinsic Alpha fair value
Locked
Current Price
$26.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.